Claims-based analysis finds fluoroquinolones increase risk of neurological events shortly after dispensing, indicating potential safety concerns.
FQ episodes were associated with an increased risk for neurological and neuropsychiatric events, especially within the first 92 days after initial dispensing. Risk estimates vary by age and gender subgroups.
No takes yet. Share an insight, caveat, or question.
Wicherski et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: